CN114426951B - 利用多能干细胞制备小胶质细胞样细胞的方法 - Google Patents
利用多能干细胞制备小胶质细胞样细胞的方法 Download PDFInfo
- Publication number
- CN114426951B CN114426951B CN202011185759.3A CN202011185759A CN114426951B CN 114426951 B CN114426951 B CN 114426951B CN 202011185759 A CN202011185759 A CN 202011185759A CN 114426951 B CN114426951 B CN 114426951B
- Authority
- CN
- China
- Prior art keywords
- cells
- cell
- microglial
- medium
- culturing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 218
- 230000002025 microglial effect Effects 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 43
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims abstract description 32
- 210000001616 monocyte Anatomy 0.000 claims abstract description 53
- 210000000130 stem cell Anatomy 0.000 claims abstract description 44
- 230000006698 induction Effects 0.000 claims abstract description 27
- 238000004114 suspension culture Methods 0.000 claims abstract description 15
- 238000004113 cell culture Methods 0.000 claims abstract description 8
- 239000002609 medium Substances 0.000 claims description 65
- 230000004069 differentiation Effects 0.000 claims description 62
- 238000012258 culturing Methods 0.000 claims description 43
- 239000000725 suspension Substances 0.000 claims description 27
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 23
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 20
- 239000006285 cell suspension Substances 0.000 claims description 14
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 14
- 230000001464 adherent effect Effects 0.000 claims description 13
- 210000005087 mononuclear cell Anatomy 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 9
- 229930182555 Penicillin Natural products 0.000 claims description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 229940049954 penicillin Drugs 0.000 claims description 7
- 229960005322 streptomycin Drugs 0.000 claims description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 238000007664 blowing Methods 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 2
- 239000012574 advanced DMEM Substances 0.000 claims description 2
- 210000000270 basal cell Anatomy 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 12
- 230000006870 function Effects 0.000 abstract description 11
- 238000001727 in vivo Methods 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 238000011081 inoculation Methods 0.000 abstract 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 20
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 20
- 102000004127 Cytokines Human genes 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 19
- 210000002242 embryoid body Anatomy 0.000 description 17
- 210000002540 macrophage Anatomy 0.000 description 16
- 108010002386 Interleukin-3 Proteins 0.000 description 15
- 102100039064 Interleukin-3 Human genes 0.000 description 15
- 210000002220 organoid Anatomy 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 229940076264 interleukin-3 Drugs 0.000 description 13
- 230000002757 inflammatory effect Effects 0.000 description 12
- 102100033499 Interleukin-34 Human genes 0.000 description 11
- 101710181549 Interleukin-34 Proteins 0.000 description 11
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 10
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 229940126864 fibroblast growth factor Drugs 0.000 description 9
- 210000000274 microglia Anatomy 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 101150021185 FGF gene Proteins 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 5
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000004498 neuroglial cell Anatomy 0.000 description 5
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 4
- 102100022338 Integrin alpha-M Human genes 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 101000890626 Homo sapiens Allograft inflammatory factor 1 Proteins 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000008672 reprogramming Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 206010012667 Diabetic glaucoma Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 101001120086 Homo sapiens P2Y purinoceptor 12 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000598051 Homo sapiens Transmembrane protein 119 Proteins 0.000 description 2
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 102100026171 P2Y purinoceptor 12 Human genes 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102100037029 Transmembrane protein 119 Human genes 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000004382 visual function Effects 0.000 description 2
- 210000001325 yolk sac Anatomy 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102000012428 Hematopoietic Cell Growth Factors Human genes 0.000 description 1
- 108010022580 Hematopoietic Cell Growth Factors Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000021320 Nasu-Hakola disease Diseases 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- -1 SCF Proteins 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000001020 neural plate Anatomy 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 208000031334 polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011185759.3A CN114426951B (zh) | 2020-10-29 | 2020-10-29 | 利用多能干细胞制备小胶质细胞样细胞的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011185759.3A CN114426951B (zh) | 2020-10-29 | 2020-10-29 | 利用多能干细胞制备小胶质细胞样细胞的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114426951A CN114426951A (zh) | 2022-05-03 |
CN114426951B true CN114426951B (zh) | 2024-05-14 |
Family
ID=81309423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011185759.3A Active CN114426951B (zh) | 2020-10-29 | 2020-10-29 | 利用多能干细胞制备小胶质细胞样细胞的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114426951B (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998039415A1 (fr) * | 1997-03-05 | 1998-09-11 | Japan Science And Technology Corporation | Microgliocyte etabli |
WO2002004618A1 (en) * | 2000-07-10 | 2002-01-17 | University Of British Columbia | Methods of producing and using a human microglial cell line |
CN104513808A (zh) * | 2013-09-30 | 2015-04-15 | 复旦大学附属眼耳鼻喉科医院 | 一种视网膜高趋化性的大鼠视网膜小胶质细胞系 |
CN109082411A (zh) * | 2018-09-07 | 2018-12-25 | 张进 | 一种通过多能干细胞分化获得具有吞噬功能的巨噬细胞的方法 |
CN109963940A (zh) * | 2016-09-02 | 2019-07-02 | 宝生物工程株式会社 | 从多能干细胞获得小胶质细胞的方法 |
CN110050061A (zh) * | 2016-10-05 | 2019-07-23 | 富士胶片细胞动力公司 | 从具有MeCP2破坏的诱导多能干细胞生成成熟谱系 |
CN110205295A (zh) * | 2019-06-25 | 2019-09-06 | 中国科学院动物研究所 | 一种多能干细胞诱导产生小胶质细胞的方法及试剂盒 |
CN110846277A (zh) * | 2019-11-14 | 2020-02-28 | 南通大学 | 一种永生化的小鼠小胶质细胞系B6Mi1及其建立方法和应用 |
CN111088229A (zh) * | 2019-11-21 | 2020-05-01 | 中山大学中山眼科中心 | 一种人多能干细胞来源的视网膜前体细胞的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10081792B2 (en) * | 2014-12-31 | 2018-09-25 | Wisconsin Alumni Research Foundation | Derivation of human microglia from pluripotent stem cells |
AU2017228466B2 (en) * | 2016-03-03 | 2023-05-25 | New York Stem Cell Foundation, Inc. | Microglia derived from pluripotent stem cells and methods of making and using the same |
EP4272551A3 (en) * | 2017-02-28 | 2024-03-06 | The Regents of the University of California | Differentiation and use of human microglia-like cells from pluripotent stem cells and hematopoietic progenitors |
-
2020
- 2020-10-29 CN CN202011185759.3A patent/CN114426951B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998039415A1 (fr) * | 1997-03-05 | 1998-09-11 | Japan Science And Technology Corporation | Microgliocyte etabli |
WO2002004618A1 (en) * | 2000-07-10 | 2002-01-17 | University Of British Columbia | Methods of producing and using a human microglial cell line |
CN104513808A (zh) * | 2013-09-30 | 2015-04-15 | 复旦大学附属眼耳鼻喉科医院 | 一种视网膜高趋化性的大鼠视网膜小胶质细胞系 |
CN109963940A (zh) * | 2016-09-02 | 2019-07-02 | 宝生物工程株式会社 | 从多能干细胞获得小胶质细胞的方法 |
CN110050061A (zh) * | 2016-10-05 | 2019-07-23 | 富士胶片细胞动力公司 | 从具有MeCP2破坏的诱导多能干细胞生成成熟谱系 |
CN109082411A (zh) * | 2018-09-07 | 2018-12-25 | 张进 | 一种通过多能干细胞分化获得具有吞噬功能的巨噬细胞的方法 |
CN110205295A (zh) * | 2019-06-25 | 2019-09-06 | 中国科学院动物研究所 | 一种多能干细胞诱导产生小胶质细胞的方法及试剂盒 |
CN110846277A (zh) * | 2019-11-14 | 2020-02-28 | 南通大学 | 一种永生化的小鼠小胶质细胞系B6Mi1及其建立方法和应用 |
CN111088229A (zh) * | 2019-11-21 | 2020-05-01 | 中山大学中山眼科中心 | 一种人多能干细胞来源的视网膜前体细胞的制备方法 |
Non-Patent Citations (8)
Title |
---|
A novel in vitro human microglia model: Characterization of human monocyte-derived microglia;Samar Etemad et al.;《Journal of Neuroscience Methods》;79-89 * |
Efficient derivation of microglia-like cells from human pluripotent stem cells;Julien Muffat et al.;《nature medicine》;1-10 * |
Generation of defined neural populations from pluripotent stem cells;Sarah F. McComish et al.;《The Royal Society》;1-14 * |
Robust and Highly-Efficient Differentiation of Functional Monocytic Cells from Human Pluripotent Stem Cells under Serum- and Feeder Cell-Free Conditions;Masakatsu D. Yanagimachi et al.;《PLOS ONE》;第8卷(第4期);e59243 * |
人诱导多潜能干细胞在体外分化成小胶质细胞的研究进展;高艳等;《中国组织化学与细胞化学杂志》;第27卷(第4期);第378-381页 * |
小胶质细胞在糖尿病视网膜病变中的作用机制;张祚等;《神经损伤与功能重建》;第15卷(第6期);340-343 * |
视网膜小胶质细胞与眼科疾病;王爱玲等;《国外医学眼科学分册》;第28卷(第6期);418-421 * |
高艳等.人诱导多潜能干细胞在体外分化成小胶质细胞的研究进展.《中国组织化学与细胞化学杂志》.2018,第27卷(第4期),第378-381页. * |
Also Published As
Publication number | Publication date |
---|---|
CN114426951A (zh) | 2022-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001234998B2 (en) | Isolation and transplantation of retinal stem cells | |
Desbaillets et al. | Embryoid bodies: an in vitro model of mouse embryogenesis | |
KR100449141B1 (ko) | 간엽 간세포를 신경세포로 분화시키는 방법 | |
US11339372B2 (en) | Serum-free medium inducing differentiation of umbilical cord mesenchymal stem cell into insulin-secretion-like cell and preparation method and use thereof | |
AU2001234998A1 (en) | Isolation and transplantation of retinal stem cells | |
KR101753630B1 (ko) | 줄기세포의 분화 촉진 및 세포의 증식 촉진용 조성물과 그 제조방법 | |
CN105331575B (zh) | 一种人血管内皮祖细胞的高效扩增培养体系 | |
KR102123268B1 (ko) | 히알루론산을 포함하는 줄기세포 유래 엑소좀 생성 촉진 및 줄기세포능 증가용 조성물 | |
CN114752565B (zh) | 带有免疫细胞的视网膜类器官及其构建方法 | |
CN113549596B (zh) | 一种诱导培养基及其使用方法和应用 | |
CN100554409C (zh) | 使间充质干细胞分化成神经细胞的方法 | |
CN115404218A (zh) | 一种包含胶质细胞的3d人脑类器官培养方法 | |
US20050196864A1 (en) | Induction and high-yield preparative purification of mesencephalic dopaminergic neuronal progenitor cells and dopaminergic neurons from human embryonic stem cells | |
JP2006512060A (ja) | ヒト幹細胞の材料および方法 | |
CN114426951B (zh) | 利用多能干细胞制备小胶质细胞样细胞的方法 | |
KR102199636B1 (ko) | 인터페론-감마를 포함하는 줄기세포 유래 엑소좀 생성 촉진 및 줄기세포능 증가용 조성물 | |
Ibtisham et al. | The optimized condition for the isolation and in vitro propagation of mouse spermatogonial stem cells | |
Nguyen et al. | Isolation of female germline stem cells from porcine ovarian tissue and differentiation into oocyte-like cells | |
US20120308530A1 (en) | Materials Composition and Methods to Control Neural Progenitor and Stem Cell Attachment, Proliferation and Guide Cell Differentiation | |
CN118028229B (zh) | 一种从神经类器官获得间充质干细胞的制备方法 | |
WO2004090119A1 (fr) | Procede de production de cellules souches embryonnaires au moyen d'une technique de transfert de noyau de cellule somatique | |
CN115927186B (zh) | 一种培养基及其在胎猴神经干细胞分离培养中的应用 | |
CN112980775B (zh) | 一种基于多能干细胞分化制备角质细胞的培养液 | |
KR101177869B1 (ko) | 옥트(Oct)-4 발현능을 가지는 피부 유래 다분화능 성체줄기세포 및 그의 제조방법 | |
KR20100116812A (ko) | 세포응집을 이용한 심장줄기세포의 유도, 배양 방법 및 이 방법에 의해 제조된 줄기세포 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240523 Address after: 101 Beijing Dart International Innovation Platform T117, Building B, Innovation Building, No. 29 Life Park Road, Life Science Park, Changping District, Beijing 102206 Patentee after: Beijing Mengmu Biotechnology Co.,Ltd. Country or region after: China Address before: 102206 Room 301, building 6, area 1, No.8, shengshengyuan Road, Life Science Park, Changping District, Beijing Patentee before: Beijing saierpaiteng technology consulting partnership (L.P.) Country or region before: China |